Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.
Ajinomoto Adds Gene Therapy to CDMO Scope via $554M Forge Bio Buyout
